Javier Manero

Zaragoza, AR, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Journal: Rheumatology (Oxford, England)

Published: July 22, 2025

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.

Journal: Reumatologia clinica

Published: December 24, 2024

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Journal: Lupus science & medicine

Published: October 19, 2023

Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.

Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.

Journal: European journal of clinical investigation

Published: May 09, 2023

Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.

Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.

Journal: Musculoskeletal care

Published: July 14, 2022

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.

Journal: RMD open

Published: September 09, 2021

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.

Journal: Annals of the rheumatic diseases

Published: May 12, 2020

Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.

Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.

Journal: Medicine

Published: March 30, 2020

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 29, 2018

Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.

Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.

Journal: Rheumatology international

Published: August 01, 2018

Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.

Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.

Journal: Ophthalmology

Published: November 05, 2017

Objectives and methodology of BIOBADASER phase iii.

Objectives and methodology of BIOBADASER phase iii.

Journal: Reumatologia clinica

Published: May 03, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026